Global Inclusion Body Myositis Market Size By Type (ACE-083, Aceneuramic Acid ER), By Application (Research Center, Hospital), By Region, And Segment Forecasts, 2023 to 2032

The Global Inclusion Body Myositis (IBM) Market was valued at USD 398 million in 2023 and is projected to reach USD 736 million by 2031, expanding at a CAGR of 7.9% during the forecast period from 2023 to 2031. IBM is a progressive inflammatory muscle disease that leads to muscle weakness and degeneration, particularly in older adults. The market growth is primarily driven by increasing disease prevalence, growing awareness, advancements in diagnostic techniques, and ongoing clinical trials aimed at discovering effective treatments for this currently untreatable disorder.

Drivers:

1. Rising Prevalence of Inclusion Body Myositis:

The aging global population, especially in developed countries, has led to an increase in the number of IBM cases. With no definitive cure, the growing patient pool continues to drive the demand for diagnostic and supportive care options.

2. Advancements in Diagnostic Techniques:

Improved MRI imaging, genetic testing, and muscle biopsy techniques have enhanced early and accurate diagnosis of IBM, leading to better management and increasing demand for supportive therapies.

3. Expanding Research and Clinical Trials:

Pharmaceutical companies and research institutes are investing heavily in developing potential therapeutics, including immunotherapies and gene therapies, fueling optimism and growth in the IBM market.

Restraints:

1. Lack of Effective Treatment Options:

Despite ongoing research, there is currently no approved treatment that halts or reverses the progression of IBM. This therapeutic gap limits market scalability.

2. Limited Awareness in Developing Regions:

Awareness of IBM is relatively low in underdeveloped and developing regions, leading to delayed diagnoses and underreporting, which constrains overall market penetration.

Opportunity:

1. Emergence of Novel Therapeutics and Orphan Drug Designations:

Opportunities lie in the development of novel therapies granted orphan drug status by regulatory bodies, which offer tax incentives, market exclusivity, and fast-track approvals, boosting R&D investment.

2. Growing Investment in Neuromuscular Disease Research:

With increased global funding and collaborations between biotech firms and academic institutions, the development pipeline for IBM treatments is expanding, offering substantial market growth potential.

Market by System Type Insights:

The market by system type is segmented into Diagnostic Tools and Therapeutics. In 2023, the Diagnostic Tools segment dominated due to the lack of curative therapies and the growing emphasis on early diagnosis. However, the Therapeutics segment is expected to experience the fastest growth through 2031, driven by advancements in drug development and pipeline maturation.

Market by End-use Insights:

By end-use, the Hospitals and Specialty Clinics segment held the largest market share in 2023, attributed to higher patient footfall and access to diagnostic facilities. The Research & Academic Institutions segment is projected to grow significantly as more institutions participate in IBM-related clinical research and trials.

Market by Regional Insights:

North America emerged as the leading region in 2023, supported by a high prevalence of IBM, robust healthcare infrastructure, and an active R&D environment. Europe follows closely due to favorable regulatory support for rare disease treatment development. The Asia-Pacific region is anticipated to witness the fastest growth due to rising healthcare investments and increasing disease awareness.

Competitive Scenario:

Key players in the Global Inclusion Body Myositis Market include Alexion Pharmaceuticals, Orphazyme A/S, Novartis AG, Biogen Inc., Pfizer Inc., and Sanofi S.A. These companies are leveraging strategic partnerships, pipeline expansions, and orphan drug designations to strengthen their market positions.

Key Market Developments:

In 2023, Biogen announced the initiation of Phase II trials for its novel anti-inflammatory agent targeting IBM.

Orphazyme A/S secured FDA orphan drug status in 2024 for its investigational therapy targeting inclusion body myositis.

In 2025, Alexion Pharmaceuticals expanded its rare neuromuscular disorders division to include IBM-focused research initiatives.

Scope of Work – Global Inclusion Body Myositis Market

FAQs:

1) What is the current market size of the Global Inclusion Body Myositis Market?

The market was valued at USD 398 million in 2023.

2) What is the major growth driver of the Global Inclusion Body Myositis Market?

Key growth drivers include rising disease prevalence, improvements in diagnostic tools, and robust clinical research activity.

3) Which is the largest region during the forecast period in the Global Inclusion Body Myositis Market?

North America dominates the market due to its advanced healthcare systems and focus on rare disease research.

4) Which segment accounted for the largest market share in the Global Inclusion Body Myositis Market?

The Diagnostic Tools segment led the market in 2023 owing to the absence of curative treatments.

5) Who are the key market players in the Global Inclusion Body Myositis Market?

Major players include Alexion Pharmaceuticals, Orphazyme A/S, Biogen Inc., Pfizer Inc., Novartis AG, and Sanofi S.A.